Pages that link to "Q1295013"
Jump to navigation
Jump to search
The following pages link to contraceptive patch (Q1295013):
Displayed 50 items.
- (Q13019142) (redirect page) (← links)
- Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy (Q21093298) (← links)
- Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial (Q33945965) (← links)
- A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). (Q34114548) (← links)
- The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns (Q34257344) (← links)
- Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study (Q34506721) (← links)
- The transdermal contraceptive patch: a new approach to hormonal contraception. (Q34625387) (← links)
- Ortho Evra, a new contraceptive patch (Q35101469) (← links)
- Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites (Q35803655) (← links)
- The contraceptive patch. Latest developments (Q36515440) (← links)
- A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch (Q36654282) (← links)
- Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women (Q36916970) (← links)
- The transdermal contraceptive patch: an updated review of the literature (Q36992749) (← links)
- Review: contraceptive patch and vaginal ring are as effective as oral contraceptives. (Q37278770) (← links)
- Safety, efficacy and patient acceptability of the combined estrogen and progestin transdermal contraceptive patch: a review (Q37405515) (← links)
- Mathematical modeling of the release of active ingredients from a contraceptive patch: ortho evra(®) as a case study (Q37700693) (← links)
- An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch (Q37705668) (← links)
- The pharmacokinetics of 12-week continuous contraceptive patch use. (Q38913006) (← links)
- Adolescents' experiences using the contraceptive patch versus pills (Q39977363) (← links)
- Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population (Q40301876) (← links)
- Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill (Q41590779) (← links)
- Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women (Q41739761) (← links)
- Systemic photosensitivity due to a contraceptive patch (Q42971771) (← links)
- The statement of Polish Gynecological Society experts about transdermal contraceptive patch (Q43128143) (← links)
- Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study (Q43160591) (← links)
- Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study (Q43456960) (← links)
- Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise (Q43836973) (← links)
- Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants (Q43845573) (← links)
- Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women (Q43889836) (← links)
- Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions (Q43889839) (← links)
- Immediate versus delayed initiation of the contraceptive patch after abortion: a randomized trial (Q44215259) (← links)
- Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile (Q44405813) (← links)
- An evaluation of the use of the transdermal contraceptive patch in adolescents (Q44849080) (← links)
- Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise (Q44980635) (← links)
- New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study (Q45008123) (← links)
- Hormonal contraceptive patch (Q45130912) (← links)
- Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers (Q45254954) (← links)
- Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. (Q45901784) (← links)
- The risk of unintended pregnancies in users of the contraceptive patch compared to users of oral contraceptives in the UK General Practice Research Database. (Q45920159) (← links)
- Confronting the legal risks of prescribing the contraceptive patch with ongoing litigation. (Q46001460) (← links)
- Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch (Q46083890) (← links)
- Sexual function in first-time contraceptive ring and contraceptive patch users (Q46270474) (← links)
- Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study (Q46529425) (← links)
- A clinical study of transdermal contraceptive patch in Thai adolescence women (Q46663416) (← links)
- Contraceptive patch: new labeling (Q46673616) (← links)
- Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables (Q46786863) (← links)
- How should we advise patients about the contraceptive patch, given the FDA warning? (Q46917848) (← links)
- Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years. (Q46934195) (← links)
- The contraceptive patch in relation to ischemic stroke and acute myocardial infarction (Q48297939) (← links)
- Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study. (Q51072723) (← links)